Neumora Therapeutics, Inc. NMRA
0.68
(0.02)
(2.86%)
as of 25 Sep
- Market cap
- $135.3M
- P/E
- 0.0×
Follow NMRA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
6.85 | 5.87 | 5.09 | 4.50 |
Net Debt/EBITDA |
2.59 | 2.23 | 1.79 | 1.53 | |
Debt/Assets |
11.00% | 28.54% | 34.42% | 42.25% | |
Debt/Equity |
0.15 | 0.53 | 0.75 | 1.19 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 0.81 | 0.87 | 0.92 | |
Capex/Depreciation |
(0.08) | 0.06 | 0.17 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.29) | (0.29) | (0.26) | (0.21) | |
Cash per Share |
1.06 | 1.12 | 0.82 | 0.63 | |
Shareholders Equity per Share |
0.82 | 0.64 | 0.39 | 0.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.82 | 0.64 | 0.39 | 0.24 | |
Free Cash Flow |
(46.56) | (47.89) | (46.33) | (39.53) | |
Working Capital |
151.24 | 158.09 | 123.32 | 97.10 | |
Capital Expenditures |
0.07 | 0.06 | 0.07 | 0.00 | |
Net Current Asset Value |
131.41 | 103.36 | 70.24 | 44.14 | |
| Other line items | |||||
Quick Ratio |
6.64 | 5.62 | 4.88 | 4.21 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.29) | (0.29) | (0.26) | (0.21) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.33 | 3.34 | 3.05 | 2.40 | |
Average Assets |
265.19 | 254.01 | 205.31 | 174.54 | |
Average Common Equity |
226.45 | 195.47 | 149.52 | 113.70 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates